Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Inhibitor Therapeutics's operating assets for the quarter that ended in Mar. 2026 was $0.14 Mil. Inhibitor Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was $3.35 Mil. Inhibitor Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $2.51 Mil. Therefore, Inhibitor Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -1.28.
Inhibitor Therapeutics Scaled Net Operating Assets Related Terms
Inhibitor Therapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Inhibitor Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibitor Therapeutics Scaled Net Operating Assets Chart
INTI vs TPST, AKTX, ICU: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Inhibitor Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibitor Therapeutics Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Inhibitor Therapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of -1.28 mean?
Inhibitor Therapeutics (INTI) has a Scaled Net Operating Assets of -1.28 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Inhibitor Therapeutics and its competitors.
Is Inhibitor Therapeutics' Scaled Net Operating Assets too high?
Inhibitor Therapeutics' current Scaled Net Operating Assets is -1.28.
How does Inhibitor Therapeutics' Scaled Net Operating Assets compare to TPST and AKTX?
Inhibitor Therapeutics' Scaled Net Operating Assets of -1.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Inhibitor Therapeutics and its competitors. Inhibitor Therapeutics's current Scaled Net Operating Assets is -1.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibitor Therapeutics stock overvalued right now?
Inhibitor Therapeutics (INTI) has a current Scaled Net Operating Assets of -1.28. The current Scaled Net Operating Assets is -1.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Inhibitor Therapeutics (INTI), the current Scaled Net Operating Assets is -1.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and potentially commercializing therapeutics based on already approved active pharmaceutical ingredients, with a primary focus on basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. The Company develops therapeutics with patent-protected methods of use or delivery for certain cancers and non-cancerous proliferation disorders, and focuses on therapies for basal cell carcinoma (BCC) in the United States, utilizing itraconazole, an FDA-approved drug for fungal infections, with developed intellectual property and know-how related to the treatment of cancer patients using itraconazole.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INTI has been successfully added to your 
